Jenna Payesko

The podiatrist and chief executive officer of Naboso Technology spoke about the potential of textured insoles to help patients with multiple sclerosis improve gait, posture, and balance.

This is the first neurotoxin treatment approved for pediatrics 2 to 17 years of age with upper limb spasticity.

Four of the 7 patients exhibited significant improvement in all assessed study parameters, which included reduction in the Apnea-Hypopnea Index scale and an improvement in oxygen desaturation index, with 1 patient demonstrating mild improvement; overall THX-110 was generally well tolerated.

Abeona Therapeutics is currently planning a phase 1/2 clinical trial to evaluate ABO-202 in Batten disease.

Solriamfetol (Sunosi, Jazz Pharmaceuticals) is expected to be available in July 2019 in the United States.

The FDA has set a PDUFA date of March 25, 2020.

The assistant clinical investigator, Neuro Vascular Brain Imaging Unit, NINDS, further elaborated on the findings of a retrospective analysis that reported that approximately half of stroke patients who present outside of thrombolysis treatment time windows without large vessel occlusion may benefit from reperfusion therapy.

The sleep specialist and neurologist at Boston Children's Hospital spoke about managing pediatric narcolepsy from a behavioral standpoint independent of pharmacological use.

Diroximel fumarate may be an effective treatment option in both newly diagnosed and interferon/glatiramer acetate switch patients. Interim results show it significantly reduced disease activity and was well tolerated, with low rates of gastrointestinal adverse effects leading to treatment discontinuation.

In an interview with NeurologyLive, the vice president of neurosurgery at INSIGHTEC spoke about the clinical impact that the Exablate Neuro device has had on the treatment of tremor since its FDA approval.

This device, which is being prepared to launch in the US market later this year, is an alternative treatment option for acute migraine.

The subgroups were defined by baseline characteristics that are known to be potential modifiers of risk to conversion to clinically-definite multiple sclerosis, including age, gender, first classification of demyelinating event, presence of T1 Gd+ lesions, and number of active T2 lesions.

The Director of the Multiple Sclerosis and Hereditary Neuropathy Centers at Seton Hall-Hackensack Meridian School of Medicine shared insight into what clinicians should know about Charcot-Marie-Tooth disease.

Similar rates of successful clinical and procedural EVT outcomes were reported in patients with and without prestroke disability; however, prospective studies are needed to confirm this finding.

This is the second aneurysm adjunctive stent to be granted premarket approval for treatment of wide-neck, intracranial aneurysms in conjunction with embolic detachable coils.

The recommendations translate important scientific knowledge and innovations in clinical care into improvements in patient outcomes.

Nayzilam is now the first and only FDA-approved nasal option for treating seizure clusters.

NfL levels were reduced during treatment with fingolimod, providing further evidence of the long-term benefit of the drug and demonstrating a greater impact of highly effective therapy in relapsing-remitting multiple sclerosis.

The FDA has expanded the indication for incobotulinumtoxinA, making it a first-line treatment for blepharospasm.

The investigational candidate is the subject of the 2-part phase 2/3 SUNFISH trial in young adult and pediatric patients with type 2 and type 3 SMA.

NeurologyLive spoke with the director of the Cleveland Clinic Lou Ruvo Center for Brain Health to learn why, despite hundreds of failed trials and therapies, there is growing excitement for what's to come.

The Assistant Professor at the University of Alabama School of Medicine spoke about the results of a recent cohort study that found that a shorter, yet deeper therapeutic coma may be safer and more effective than the currently recommended therapeutic coma duration for refractory status epilepticus.

The study provides class 2A and Level B evidence that DOAC therapy started in a median of 5 days following ischemic stroke in patients with atrial fibrillation is beneficial compared with VKA therapy.

A prespecified futility analysis of a phase 3 study revealed that the primary endpoint of mean change from baseline in the weekly average number of cluster headache attacks during the 4-week treatment period is unlikely to be met.

The phase 1 results support the initiation of the phase 2/3 clinical trial which is expected to initiate in July 2019.

In an ongoing phase 2 study, 21 nonambulatory participants with Duchenne muscular dystrophy passed the 52-week treatment mark.

A shorter yet deeper therapeutic coma for treatment of refractory status epilepticus may be more effective and safer than the currently recommended therapeutic coma duration of 24 to 48 hours.

The FDA cited 2 deficiencies in the NDA: certain nonclinical studies were not included to allow for assessment of chronic administration of fenfluramine; and an incorrect version of the clinical data was submitted.

The planned phase 1/2 trial of the recombinant AAV5 vector treatment, the first one-time administered AAV gene therapy to enter clinical testing for Huntington disease, is expected to begin dosing patients in the second half of 2019.

The Senior Vice President for Research and Training at Kessler Foundation discussed how cognitive rehabilitation is one approach to addressing cognitive problems in multiple sclerosis.